{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:15:20Z","timestamp":1791918920041,"version":"4.3.4"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system (CNS), characterized by inflammation and neurodegeneration. The pathophysiology of MS, especially its progressive forms, involves various cellular components, including microglia, the primary resident immune cells of the CNS. This review discusses the role of microglia in neuroinflammation, tissue repair, and neural homeostasis, as well as their involvement in MS and explores potential therapeutic strategies targeting microglial function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A literature search conducted in August 2023 and updated in March 2025, using the PubMed database, focused on articles relating to microglia and MS published in 2018\u20132025. Additionally, ongoing clinical trials of Bruton\u2019s tyrosine kinase (BTK) inhibitors were identified through the ClinicalTrials.gov website in November 2023 and updated in March 2025.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Microglia are highly adaptive and exhibit various functional states throughout different life stages and play critical roles in neuroinflammation, tissue repair, and neural homeostasis. Their altered activity is a prominent feature of MS, contributing to its pathogenesis. Imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) provide insights into microglial activity in MS. BTK inhibitors and other novel treatments for MS, including masitinib and frexalimab, show promise in modulating microglial function and influencing the disease progression rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The multifaceted roles of microglia in CNS development, immune surveillance, and particularly in the pathogenesis of MS highlight the potential of targeting microglial functions in MS treatment. Emerging research on the involvement of microglia in MS pathophysiology offers promising avenues for developing novel therapies, especially for progressive MS, potentially improving patient outcomes in this debilitating disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1495529","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:11:15Z","timestamp":1747282275000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["The role of microglia in multiple sclerosis: implications for treatment with Bruton\u2019s tyrosine kinase inhibitors"],"prefix":"10.3389","volume":"16","author":[{"given":"Patrick","family":"Vermersch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Airas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Deisenhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Grigoriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Pugliatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Van Wijmeersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magd","family":"Zakaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Oreja-Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/wco.0000000000000622","article-title":"Multiple sclerosis: clinical aspects","volume":"31","author":"Oh","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00718-z","article-title":"The immunology of multiple sclerosis","volume":"22","author":"Attfield","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.31128\/AJGP-07-21-6103","article-title":"Multiple sclerosis: Diagnosis, disease-modifying therapy and prognosis","volume":"51","author":"Travers","year":"2022","journal-title":"Aust J Gen Pract"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler"},{"key":"B5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0035-2","article-title":"Progressive multiple sclerosis: from pathophysiology to therapeutic strategies","volume":"18","author":"Faissner","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2018.11.005","article-title":"Microglia in central nervous system inflammation and multiple sclerosis pathology","volume":"25","author":"Voet","year":"2019","journal-title":"Trends Mol Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061507","article-title":"Retinal and brain microglia in multiple sclerosis and neurodegeneration","volume":"10","author":"Choi","year":"2021","journal-title":"Cells"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2023.07.006","article-title":"Bruton\u2019s tyrosine kinase inhibitors for multiple sclerosis treatment: A new frontier","volume":"42","author":"Greenberg","year":"2024","journal-title":"Neurol Clin"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat0473","article-title":"Glia as architects of central nervous system formation and function","volume":"362","author":"Allen","year":"2018","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2019.09.004","article-title":"Cien a\u00f1os de microgl\u00eda: milestones in a century of microglial research","volume":"42","author":"Sierra","year":"2019","journal-title":"Trends Neurosci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-093019-110159","article-title":"Microglia and central nervous system-associated macrophages - from origin to disease modulation","volume":"39","author":"Prinz","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.00198","article-title":"Overview of general and discriminating markers of differential microglia phenotypes","volume":"14","author":"Jurga","year":"2020","journal-title":"Front Cell Neurosci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3109\/00207454.2013.833510","article-title":"Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer\u2019s disease","volume":"124","author":"Cai","year":"2014","journal-title":"Int J Neurosci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00374","article-title":"Microglia in multiple sclerosis: Friend or foe","volume":"11","author":"Guerrero","year":"2020","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-019-0609-8","article-title":"Microglial regional heterogeneity and its role in the brain","volume":"25","author":"Tan","year":"2020","journal-title":"Mol Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26877","article-title":"Transcript profiles of microglia\/macrophage cells at the borders of chronic active and subpial gray matter lesions in multiple sclerosis","volume":"95","author":"Chomyk","year":"2024","journal-title":"Ann Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1194637","article-title":"Fate mapping analysis reveals that adult microglia derive from primitive macrophages","volume":"330","author":"Ginhoux","year":"2010","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.698420","article-title":"Siglec-H-deficient mice show enhanced type I IFN responses, but do not develop autoimmunity after influenza or LCMV infections","volume":"12","author":"Szumilas","year":"2021","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.kint.2016.10.015","article-title":"Activated ERK1\/2 increases CD44 in glomerular parietal epithelial cells leading to matrix expansion","volume":"91","author":"Roeder","year":"2017","journal-title":"Kidney Int"},{"key":"B23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3892\/br.2020.1402","article-title":"Functions of CD169 positive macrophages in human diseases (Review)","volume":"14","author":"Liu","year":"2021","journal-title":"BioMed Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.cell.2019.08.053","article-title":"Microglia biology: One century of evolving concepts","volume":"179","author":"Prinz","year":"2019","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05534-y","article-title":"Microglia regulate central nervous system myelin growth and integrity","volume":"613","author":"McNamara","year":"2023","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad8670","article-title":"Microglia development follows a stepwise program to regulate brain homeostasis","volume":"353","author":"Matcovitch-Natan","year":"2016","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806682105","article-title":"Microglial activation and TNFalpha production mediate altered CNS excitability following peripheral inflammation","volume":"105","author":"Riazi","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.neuint.2013.04.007","article-title":"Microglia are the major source of TNF-alpha and TGF-beta1 in postnatal glial cultures; regulation by cytokines, lipopolysaccharide, and vitronectin","volume":"63","author":"Welser-Alves","year":"2013","journal-title":"Neurochem Int"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13139","article-title":"Microglial M1\/M2 polarization and metabolic states","volume":"173","author":"Orihuela","year":"2016","journal-title":"Br J Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2022.10.020","article-title":"Microglia states and nomenclature: A field at its crossroads","volume":"110","author":"Paolicelli","year":"2022","journal-title":"Neuron"},{"key":"B31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s40478-019-0850-z","article-title":"Regulation of microglial TMEM119 and P2RY12 immunoreactivity in multiple sclerosis white and grey matter lesions is dependent on their inflammatory environment","volume":"7","author":"van Wageningen","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-55529-9_34","article-title":"Metabolic control of microglia","volume":"37","author":"Garcia-Segura","year":"2024","journal-title":"Adv Neurobiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105290","article-title":"Microglia reprogram metabolic profiles for phenotype and function changes in central nervous system","volume":"152","author":"Yang","year":"2021","journal-title":"Neurobiol Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.00246","article-title":"Microglia gone awry: linking immunometabolism to neurodegeneration","volume":"14","author":"Afridi","year":"2020","journal-title":"Front Cell Neurosci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03892-7","article-title":"A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis","volume":"597","author":"Absinta","year":"2021","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15360","article-title":"The contribution of neuropathology to multiple sclerosis research","volume":"29","author":"Lassmann","year":"2022","journal-title":"Eur J Neurol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/s1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2022.06.023","article-title":"Microglia in multiple sclerosis: Protectors turn destroyers","volume":"110","author":"Yong","year":"2022","journal-title":"Neuron"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518814117","article-title":"Slowly expanding\/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions","volume":"25","author":"Elliott","year":"2019","journal-title":"Mult Scler"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx113","article-title":"Loss of \u2018homeostatic\u2019 microglia and patterns of their activation in active multiple sclerosis","volume":"140","author":"Zrzavy","year":"2017","journal-title":"Brain"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.674189","article-title":"GPCRomics of homeostatic and disease-associated human microglia","volume":"12","author":"Hsiao","year":"2021","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00624-x","article-title":"The role of glial cells in multiple sclerosis disease progression","volume":"18","author":"Healy","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1522381","article-title":"Inflammatory microglia correlate with impaired oligodendrocyte maturation in multiple sclerosis","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24497","article-title":"Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque","volume":"78","author":"Frischer","year":"2015","journal-title":"Ann Neurol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106268","article-title":"Cerebrospinal fluid biomarkers as predictors of multiple sclerosis severity","volume":"94","author":"Tolentino","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"B47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13024-025-00801-8","article-title":"Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications","volume":"20","author":"Mwale","year":"2025","journal-title":"Mol Neurodegener"},{"key":"B48","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12974-024-03243-z","article-title":"CX3CR1(+)\/UCHL1(+) microglial extracellular vesicles in blood: a potential biomarker for multiple sclerosis","volume":"21","author":"Duan","year":"2024","journal-title":"J Neuroinflammation"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.20198","article-title":"Susceptibility weighted imaging (SWI)","volume":"52","author":"Haacke","year":"2004","journal-title":"Magn Reson Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/mrm.25358","article-title":"Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker","volume":"73","author":"Wang","year":"2015","journal-title":"Magn Reson Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1227\/01.Neu.0000255350.71700.37","article-title":"The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system Malignancy: A pilot study","volume":"60","author":"Neuwelt","year":"2007","journal-title":"Neurosurgery"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028969","article-title":"Magnetic resonance imaging in multiple sclerosis","volume":"8","author":"Hemond","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/jmri.24768","article-title":"Susceptibility-weighted imaging and quantitative susceptibility mapping in the brain","volume":"42","author":"Liu","year":"2015","journal-title":"J Magn Reson Imaging"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00062-015-0432-9","article-title":"Quantitative susceptibility mapping: Concepts and applications","author":"Reichenbach","year":"2015","journal-title":"Clin Neuroradiol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abq2923","article-title":"Mapping microglia and astrocyte activation in vivo using diffusion MRI","volume":"8","author":"Garcia-Hernandez","year":"2022","journal-title":"Sci Adv"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00255","article-title":"Significance and in vivo detection of iron-laden microglia in white matter multiple sclerosis lesions","volume":"9","author":"Gillen","year":"2018","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1137635","article-title":"The role of iron metabolism in the pathogenesis and treatment of multiple sclerosis","volume":"14","author":"Duarte-Silva","year":"2023","journal-title":"Front Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.1038\/s41598-022-08477-6","article-title":"Disease correlates of rim lesions on quantitative susceptibility mapping in multiple sclerosis","volume":"12","author":"Marcille","year":"2022","journal-title":"Sci Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.21.26777","article-title":"Paramagnetic rim lesions in multiple sclerosis: Comparison of visualization at 1.5-T and 3-T MRI","volume":"219","author":"Hemond","year":"2022","journal-title":"AJR Am J Roentgenol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2022.103205","article-title":"Cortical lesions, central vein sign, and paramagnetic rim lesions in multiple sclerosis: Emerging machine learning techniques and future avenues","volume":"36","author":"La Rosa","year":"2022","journal-title":"NeuroImage Clin"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2399","article-title":"Association of chronic active multiple sclerosis lesions with disability","volume":"76","author":"Absinta","year":"2019","journal-title":"vivo. JAMA Neurol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001139","article-title":"Slowly expanding lesions predict 9-year multiple sclerosis disease progression","volume":"9","author":"Preziosa","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11082-2","article-title":"MRI predictors for the conversion from contrast-enhancing to iron rim multiple sclerosis lesions","volume":"269","author":"Wenzel","year":"2022","journal-title":"J Neurol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn009","article-title":"Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement","volume":"131","author":"Vellinga","year":"2008","journal-title":"Brain"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/jon.12768","article-title":"Detection of monocyte\/macrophage and microglia activation in the TMEV model of chronic demyelination using USPIO-enhanced ultrahigh-field imaging","volume":"30","author":"Zivadinov","year":"2020","journal-title":"J Neuroimaging"},{"key":"B66","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/wco.0000000000001045","article-title":"Microglia in multiple sclerosis - pathogenesis and imaging","volume":"35","author":"Airas","year":"2022","journal-title":"Curr Opin Neurol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12974-025-03343-4","article-title":"Characteristics of TSPO expression in marmoset EAE","volume":"22","author":"Falk","year":"2025","journal-title":"J Neuroinflammation"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/123.11.2321","article-title":"The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity","volume":"123","author":"Banati","year":"2000","journal-title":"Brain"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/jcbfm.2011.147","article-title":"An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28","volume":"32","author":"Owen","year":"2012","journal-title":"J Cereb Blood Flow Metab"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt145","article-title":"In vivo radioligand binding to translocator protein correlates with severity of Alzheimer\u2019s disease","volume":"136","author":"Kreisl","year":"2013","journal-title":"Brain"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz287","article-title":"A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis","volume":"142","author":"Nutma","year":"2019","journal-title":"Brain"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00537-1","article-title":"Positron emission tomography in multiple sclerosis - straight to the target","volume":"17","author":"Bodini","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.131698","article-title":"In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand \u00b9\u00b9C-PK11195","volume":"55","author":"Rissanen","year":"2014","journal-title":"J Nucl Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000691","article-title":"Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging","volume":"7","author":"Bezukladova","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200026","article-title":"Imaging characteristics of choroid plexuses in presymptomatic multiple sclerosis: a retrospective study","volume":"9","author":"Ricigliano","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcab301","article-title":"Phenotyping of multiple sclerosis lesions according to innate immune cell activation using 18 kDa translocator protein-PET","volume":"4","author":"Nylund","year":"2022","journal-title":"Brain Commun"},{"key":"B77","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/jnnp-2023-331051","article-title":"Association of serum neurofilament light with microglial activation in multiple sclerosis","volume":"94","author":"Saraste","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa275","article-title":"Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis","volume":"143","author":"Sucksdorff","year":"2020","journal-title":"Brain"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001182","article-title":"Innate immune cell-related pathology in the thalamus signals a risk for disability progression in multiple sclerosis","volume":"9","author":"Misin","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e200133","DOI":"10.1212\/nxi.0000000000200133","article-title":"TSPO-detectable chronic active lesions predict disease progression in multiple sclerosis","volume":"10","author":"Polvinen","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001180","article-title":"Retinal hyperreflecting foci associate with cortical pathology in multiple sclerosis","volume":"9","author":"Pengo","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2024.1355557","article-title":"Non-invasive in vivo imaging of brain and retinal microglia in neurodegenerative diseases","volume":"18","author":"Etebar","year":"2024","journal-title":"Front Cell Neurosci"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70038","article-title":"Hyperreflective retinal foci are associated with retinal degeneration after optic neuritis in neuromyelitis optica spectrum disorders and multiple sclerosis","volume":"32","author":"Klyscz","year":"2025","journal-title":"Eur J Neurol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-022-01229-z","article-title":"Bruton\u2019s tyrosine kinase inhibition in multiple sclerosis","volume":"22","author":"Schneider","year":"2022","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B85","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kr\u00e4mer","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00237-4","article-title":"Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: A phase 2b, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Reich","year":"2021","journal-title":"Lancet Neurol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1177\/13524585221123687","article-title":"Safety and clinical efficacy outcomes from the long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results (ECTRIMS poster: P308)","volume":"28","author":"Oh","year":"2022","journal-title":"Mult Scler J"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241234783","article-title":"Efficacy and safety results after >3.5 years of treatment with the Bruton\u2019s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a phase II randomised clinical trial with a cerebrospinal fluid sub-study","volume":"30","author":"Montalban","year":"2024","journal-title":"Mult Scler"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000208058","article-title":"Effect of evobrutinib on slowly expanding lesion volume in relapsing multiple sclerosis: A post hoc analysis of a phase 2 trial","volume":"102","author":"Arnold","year":"2024","journal-title":"Neurology"},{"key":"B91","unstructured":"Merck provides update on phase III results for evobrutinib in relapsing multiple sclerosis\n          \n          \n            \n              Merck\n              KGAA\n            \n          \n          \n          2023"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007258","article-title":"Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT","volume":"4","author":"Dubreuil","year":"2009","journal-title":"PLoS One"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001148","article-title":"Efficacy and safety of masitinib in progressive forms of multiple sclerosis: A randomized, phase 3, clinical trial","volume":"9","author":"Vermersch","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B94","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1177\/13524585211047080","article-title":"Early efficacy of ofatumumab on microglia in patients with relapsing forms of MS: Interim analysis of a 9-month study (ECTRIMS poster: P966)","volume":"27","author":"Singhal","year":"2021","journal-title":"Mult Scler J"},{"key":"B95","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2309439","article-title":"Inhibition of CD40L with frexalimab in multiple sclerosis","volume":"390","author":"Vermersch","year":"2024","journal-title":"N Engl J Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000574","article-title":"Natalizumab treatment reduces microglial activation in the white matter of the MS brain","volume":"6","author":"Sucksdorff","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11539-4","article-title":"PET-measurable innate immune cell activation reduction in chronic active lesions in PPMS brain after rituximab treatment: A case report","volume":"270","author":"Lehto","year":"2023","journal-title":"J Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1495529\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:11:18Z","timestamp":1747282278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1495529\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":97,"alternative-id":["10.3389\/fimmu.2025.1495529"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1495529","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"article-number":"1495529"}}